Skip to main content

Verrica Pharmaceuticals Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

VRCA$3.59+12.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERRICA PHARMACEUTICALS INC.
By:/s/ Jayson Rieger
March 11, 2026Jayson RiegerPresident and Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jayson Rieger and John J. Kirby, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Verrica Pharmaceuticals Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Jayson RiegerPresident, Chief Executive Officer and Director (Principal Executive Officer)March 11, 2026
Jayson Rieger
/s/ John J. KirbyInterim Chief Financial Officer(Interim Principal Financial Officer and Interim Principal Accounting Officer)March 11, 2026
John J. Kirby
/s/ Paul B. ManningChairman of the Board of DirectorsMarch 11, 2026
Paul B. Manning
/s/ Gavin CorcoranDirectorMarch 11, 2026
Gavin Corcoran
/s/ Lawrence EichenfieldDirectorMarch 11, 2026
Lawrence Eichenfield
/s/ Charles FrantzebDirectorMarch 11, 2026
Charles Frantzeb
/s/ Diem NguyenDirectorMarch 11, 2026
Diem Nguyen
/s/ Mark PrygockiDirectorMarch 11, 2026
Mark Prygocki
/s/ Sean StalfortDirectorMarch 11, 2026
Sean Stalfort
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.